If validated, defining HCC with gain of 8q may assist in identifying patients who could benefit for specific c-myc inhibitors or emerging agents that target the MAPK/ERK (mitogen-activated protein kinase)-c-myc related pathway [8,9]. This evidence concerns the gene WNK2 and hepatocellular carcinoma.